today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted ...

Attivare will use MSR biomaterial scaffolds like this to first develop treatments for patients with solid tumors and heme malignancies who do not respond to immunotherapies yet. The immune ...

Cellectis SA's pipeline consists of allogeneic CAR T-cell therapies that have the potential to make meaningful dents in heme malignancies. The financial picture remains strong, bolstered further ...

Heme Malignancies Program: TScan’s two lead TCR-T therapy candidates, TSC-100 and TSC-101, are designed to treat residual disease and prevent relapse in patients with acute myeloid leukemia (AML ...

"This is an exciting year for TScan as we advance our mission of bringing life-changing T-cell therapies to patients with both heme and solid tumor malignancies,” said Gavin MacBeath, Ph.D ...

“In the five years since its initial approval, BRUKINSA has become a standard of care for patients facing many B-cell malignancies ... M.P.H., Chief Medical Officer, Hematology at BeiGene.